Multiple myeloma treatment receives Orphan Drug Designation

Orphan Drug Designation has been granted to the CT053 anti-BCMA CAR-T programme for multiple myeloma treatment.

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CARsgen Therapeutics Inc’s investigational CAR-T cell therapy fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cells (CT053) for the treatment of multiple myeloma.

ODD is granted by the FDA Office of Orphan Products Development to pharmaceutical products which are intended for the treatment of rare diseases that affect fewer than 200,000 people in the US.

“FDA ODD is an important regulatory milestone in the continued development and commercialisation of CT053 anti-BCMA CAR-T cells,” said Dr Zonghai Li, Founder, CEO and CSO of CARsgen. “CT053 has demonstrated outstanding potency in an exploratory Phase I clinical study in China. A total of 19 of 24 patients with relapsed and refractory multiple myeloma showed complete response. And importantly, no event of grade 3 or higher cytokine release syndrome (CRS) was observed.”

The CT053 anti-BCMA CAR-T programme has also received Investigational New Drug (IND) clearance from the US FDA.

Under the Orphan Drug Act, the CT053 anti-BCMA product would be eligible for certain benefits including seven years of market exclusivity in the United States following marketing approval by the FDA.